BRCA1 Mutation Analysis in a Portuguese Population with Early-Onset Breast and/or Ovarian Cancer
نویسندگان
چکیده
The aims of our study were: (1) to detect disease-associated BRCA1 mutations in a series of Portuguese patients with breast and/or ovarian cancer; (2) to evaluate the expression of molecular markers of biological behaviour, namely ER, proliferative index, c-erb-B2, p53, sialyl-Tn and angiogenic index in a series of hereditary breast cancer (HBC) in relation to sporadic cases. We selected 65 patients consecutively diagnosed in our institute with earlyonset breast cancer. Three patients with ovarian cancer were also studied. The breast cancer cases were divided into hereditary (n = 33) and sporadic (n = 32) according to BCLC criteria. BRCA1 mutations were studied by PTT and Fragment Analysis. Direct sequencing was performed in the positive cases. Two cases with alteration in BRCA1 gene were observed. One ovarian carcinoma presented a mutation in exon 11 (3444delAAAT). A deletion in intron 1 was observed in one breast cancer case (IVS18+ 80delA). These two mutations were not previously described according to BIC web site. The histologic parameters of breast cancer cases were evaluated in tissue sections and the markers were studied by immunohistochemistry. HBC cases presented younger age of onset, higher angiogenic and proliferative indexes. There were no significant differences in tumour size, nodal status, histologic grade, ER status and expression of c-erb-B2, p53 and sialyl-Tn. In conclusion, we detected two new BRCA1 mutations in a series of early-onset breast and/or ovarian cancer patients of Portuguese origin. This is the first description of BRCA1 mutations in a Portuguese population. Abstract
منابع مشابه
Minor role of BRCA2 mutation (Exon2 and Exon11) in patients with early-onset breast cancer amongst Iranian Azeri-Turkish women
Objective(s): Breast cancer is the most common cancer in women. Every year, one million new cases are reported worldwide, representing 18% of the total number of cancer in women. Hereditary BRCA1 and BRCA2 mutations account for about 60% of inherited breast cancer and are the only known causes of hereditary breast cancer syndrome. The aim of this study was to determine the frequency of BRCA2 (e...
متن کاملشناسایی جهش های جدید در اگزون 11 ژنBRCA1 در بیماران مبتلا به سرطان پستان ارثی
Introduction: Breast cancer is the most common malignancy in women worldwide. BRCA1 is a tumor suppressor gene that is involved in DNA-damage repair. One of the significant risk factors of breast cancer is the family history. BRCA1 gene consists of 24 exons that encode a protein with 1863 amino acids. Exon 11 is the largest exons and most of the disease-linked mutations have been found in it. I...
متن کاملFunctional Investigation of the Novel BRCA1variant (Glu1661Gly) byComputationalTools andYeastTranscription Activation Assay
Introduction: Mutations in the BRCA1 gene are major risk factors for breast and ovarian cancers. However, the relationship between some BRCA1 mutations and cancer risk remains largely unknown. Cancer risk predictions could be improved by evaluation of the impairment degree in the BRCA1 functions due to a specific mutation. This study aimed to assess the functional effect of a novel variant (Glu...
متن کاملPrevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
Ductal and lobular carcinoma in situ (CIS) accounted for 62,280 (24.5%) of all new breast cancer diagnoses in 2009. BRCA1/2 mutations confer an extremely high risk of breast cancer, and management guidelines for BRCA1/2 mutation carriers advise close follow-up, intensive screening, and consideration of prophylactic surgery to lower this risk. The limited relevant previous data are not definitiv...
متن کاملمیزان بیان پروتئینBRCA1 در کارسینوم های مهاجم و درجای پستان و ارتباط آن با مارکر سلول های بنیادی سرطان پستان (CD44) و عوامل پیش آگهی تومور
Introduction : Breast cancer is the most common cancer and the second cause of cancer death among women. Despite recent developments in therapeutic tools about 25% of all the involved cases die annually. The clinical, molecular, and pathologic features of breast cancer in BRCA1 mutation carriers suggest that BRCA1 may function as a stem-cell regulator. The purpose of the current study was to ...
متن کامل